YOLFTbeta
30

Wecome Pharmaceutical Co Ltd

300878 · SHE · Healthcare / Biotechnology

33.43CNY-1.57 (-4.49%)

Price History

Full chart

Market Stats

Previous Close35.00
Open34.42
Day Range32.96 – 34.68
52-Week Range20.30 – 40.22
Volume2.68M
Market Cap4.37B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.28
Dividend Yield0.00%
Beta0.59
50-Day Avg31.94
200-Day Avg30.29

About

Zhejiang Wecome Pharmaceutical Company Limited engages in the research and development, production, and sale of modern Chinese and western medicine in China. The company offers products in various forms, including hard capsules, tablets, granules, soft capsules, pills, and other dosage forms. It also operates the retail of pharmaceutical commercial products. The company was formerly known as Zhejiang Weikang Pharmaceutical Co., Ltd. Zhejiang Wecome Pharmaceutical Company Limited was founded in 2000 and is headquartered in Lishui, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Yang Liu
  • Employees535
  • HeadquartersNo. 2, Suisong Road, Lishui, China, 323000, China
  • Websitehttps://www.zjwk.com

Leadership

  • Mr. Yang LiuChairman & GM · b. 1991
  • Ms. Jing WangFinance Director & Accounting Supervisor · b. 1987
  • Ms. Xiaoxia KongDeputy General Manager · b. 1982
  • Mr. Jingwei DingDeputy General Manager · b. 1974
  • Ms. Dong LiuDeputy General Manager · b. 1990
  • Mr. Zhang Qi ZhangDeputy General Manager · b. 1984

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue135.06M153.28M207.74M282.09M406.53M577.65M641.80M622.77M632.95M532.44M519.62M351.20M225.27M
Growth (%)-+13.49%+35.53%+35.79%+44.11%+42.09%+11.11%-2.97%+1.64%-15.88%-2.41%-32.41%-35.86%
Cost of Revenue68.75M66.02M84.89M111.03M124.37M142.30M167.77M171.42M204.38M219.08M257.69M223.40M155.29M
Gross Profit66.31M87.26M122.86M171.06M282.16M435.35M474.03M451.35M428.57M313.36M261.93M127.80M69.98M
Gross Margin49.10%56.93%59.14%60.64%69.41%75.37%73.86%72.47%67.71%58.85%50.41%36.39%31.06%
Operating Expense41.21M47.83M64.75M95.50M177.29M331.96M326.93M292.31M329.43M248.51M263.83M281.54M155.58M
Operating Income25.10M39.43M58.11M75.56M104.87M103.39M147.10M159.04M99.14M64.85M-1.90M-153.74M-85.60M
Operating Margin18.59%25.72%27.97%26.78%25.80%17.90%22.92%25.54%15.66%12.18%-0.37%-43.78%-38.00%
EBITDA22.92M29.90M63.04M104.40M115.98M111.21M160.73M171.18M116.31M98.52M49.42M-90.59M-139.32M
EBITDA Margin16.97%19.51%30.34%37.01%28.53%19.25%25.04%27.49%18.38%18.50%9.51%-25.79%-61.85%
Net Income19.75M20.72M50.02M80.85M95.16M87.78M126.01M135.82M96.50M48.81M-8.95M-147.43M-227.34M
Net Income Margin14.62%13.52%24.08%28.66%23.41%15.20%19.63%21.81%15.25%9.17%-1.72%-41.98%-100.92%
R&D8.55M9.68M12.93M14.36M15.83M16.40M21.16M20.41M37.02M39.32M42.80M14.19M9.37M
R&D as % of Total Revenue6.33%6.31%6.23%5.09%3.89%2.84%3.30%3.28%5.85%7.38%8.24%4.04%4.16%
Interest Expense1.27M--133.30K200.80K1.59M1.20M311.85K2.25M5.57M9.45M9.41M6.27M
Interest Expense % of Total Revenue0.94%--0.05%0.05%0.27%0.19%0.05%0.36%1.05%1.82%2.68%2.78%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets107.13M173.04M221.89M315.14M479.74M641.12M875.87M1.63B1.69B1.91B2.05B1.65B1.25B
Total Liabilities72.78M94.82M91.84M104.25M173.68M247.29M356.02M244.39M284.28M502.25M639.23M478.50M327.50M
Total Equity33.67M78.22M130.04M210.90M306.05M393.83M519.84M1.38B1.40B1.40B1.39B1.16B910.44M
Cash30.50M51.15M43.98M92.74M107.44M83.23M160.89M595.23M280.80M162.74M330.16M253.96M137.42M
Total Debt18.00M---28.50M70.24M164.93M14.71M82.34M319.10M425.04M201.81M-
Net Debt-12.50M-51.15M-43.98M-92.74M-78.94M-12.99M4.04M-580.51M-198.46M156.36M94.87M-52.15M15.88M

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow25.98M46.01M29.63M100.15M29.00M105.57M112.76M42.81M-67.74M146.57M58.29M-27.17M67.09M
Investing Cash Flow-7.24M-37.04M-36.13M-47.54M-36.03M-172.73M-120.98M-172.27M-192.35M-443.82M9.31M188.29M-
Financing Cash Flow-11.91M11.15M-1.63M-733.30K20.41M40.24M87.22M568.89M-53.96M178.74M97.57M-234.09M-
Capital Expenditure11.48M40.68M38.48M47.97M42.04M172.73M114.98M152.34M171.10M248.44M139.29M126.92M67.17M
Free Cash Flow14.51M5.33M-8.85M52.19M-13.04M-67.16M-2.21M-109.53M-238.84M-101.88M-81.00M-154.10M-81.74K
Dividends Paid1.51M880.55K-133.30K17.70K1.42M5.73M7.83M80.44M43.44M7.02M44.40M28.42M
FCF to OCF55.83%11.59%-29.86%52.11%-44.95%-63.61%-1.96%-255.83%352.56%-69.51%-138.96%567.09%-0.12%
Dividend Paid to FCF10.42%16.52%-0.26%-0.14%-2.12%-258.64%-7.15%-33.68%-42.64%-8.66%-28.81%-34769.93%

Earnings

Report DateSep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023May 20, 2024Jun 30, 2024Sep 30, 2024May 20, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------------
EPS Actual0.220.320.140.300.200.030.160.240.26-0.340.190.260.03-0.530.17-0.070.21-0.07-0.38-0.42-0.730.01-0.17
Surprise-----------------------
Timing--------------After-hours--After-hours-----

Key Statistics & Ratios

Market Cap4.37B
Enterprise Value4.55B
Trailing P/E0.00
Forward P/E0.00
Price / Sales18.44
Price / Book5.08
EPS-1.28
Book Value6.25
Revenue (TTM)236.86M
Gross Profit (TTM)68.04M
EBITDA-32.40M
Profit Margin-78.26%
Operating Margin-41.62%
Return on Equity-18.85%
Return on Assets-3.89%
Shares Outstanding144.79M
Shares Float36.85M
Beta0.59
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20251×
0.14May 29, 2025
20241×
0.25May 29, 2024
20221×
0.54Jun 17, 2022
20211×
0.56May 31, 2021

Stock Splits

  • Jun 17, 20221.8:1